Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy;Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA para el tratamiento antirretroviral inicial

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 29, Issue 10, 2011, Pages 721-730

  Blasco, Antonio Javier ^a   Arribas, José Ramón ^b   Clotet, Bonaventura ^c   Domingo, Pere ^d   González García, Juan ^b   López Bernaldo, Juan Carlos ^e   Llibre, Josep M ^c   Lozano, Fernando ^f   Podzamczer, Daniel ^g   Santamaría, Juan Miguel ^h   Tuset, Montserrat ⁱ   Zamora, Laura ^j   Lázaro, Pablo ^a   Gatell, Josep M ^j  

^a Tecnicas Avanzadas de Investigacion en Servicios de Salud TAISS   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h HOSPITAL DE BASURTO   (Spain)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

more..

Author keywords

AIDS; Antiretrovirals; Cost; Effectiveness; Efficiency; HIV; Therapy

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; HLA B57 ANTIGEN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR; TENOFOVIR;

ANTIVIRAL THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; MEDICAL DECISION MAKING; MEDICAL INFORMATION SYSTEM; SENSITIVITY ANALYSIS; SPAIN; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; DECISION TREES; DRUG COSTS; DRUG THERAPY, COMBINATION; DRUG TOXICITY; EXPERT TESTIMONY; HIV INFECTIONS; HUMANS; MODELS, THEORETICAL; PRACTICE GUIDELINES AS TOPIC; SPAIN; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 82755197159     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2011.08.003     Document Type: Article

References (25)

1. F.J. Palella Jr., K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, and G.A. Satten Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators N Engl J Med 338 1998 853 860 (Pubitemid 28135961)
2. A. Mocroft, S. Vella, T.L. Benfield, A. Chiesi, V. Miller, and P. Gargalianos Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group Lancet 352 1998 1725 1730 (Pubitemid 28534954)
3. B. Autran, G. Carcelain, T.S. Li, C. Blanc, D. Mathez, and R. Tubiana Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease Science 277 1997 112 116 (Pubitemid 27450659)
4. A.D. Kelleher, A. Carr, J. Zaunders, and D.A. Cooper Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir J Infect Dis 173 1996 321 329
5. N. Lohse, A.B. Hansen, G. Pedersen, G. Kronborg, J. Gerstoft, and H.T. Sorensen Survival of persons with and without HIV infection in Denmark, 1995-2005 Ann Intern Med 146 2007 87 95 (Pubitemid 351640011)
6. E.J. Beck, S. Mandalia, M. Gaudreault, C. Brewer, H. Zowall, and N. Gilmore The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001 AIDS 18 2004 2411 2418 (Pubitemid 40065908)
7. K.A. Freedberg, E. Losina, M.C. Weinstein, A.D. Paltiel, C.J. Cohen, and G.R. Seage The cost effectiveness of combination antiretroviral therapy for HIV disease N Engl J Med 344 2001 824 831 (Pubitemid 32222162)
8. S.J. Goldie, Y. Yazdanpanah, E. Losina, M.C. Weinstein, X. Anglaret, and R.P. Walensky Cost-effectiveness of HIV treatment in resource-poor settings - the case of Cote d'Ivoire N Engl J Med 355 2006 1141 1153 (Pubitemid 44394920)
9. K.M. Johnston, A.R. Levy, V.D. Lima, R.S. Hogg, M.W. Tyndall, and P. Gustafson Expanding access to HAART: a cost-effective approach for treating and preventing HIV AIDS 24 2010 1929 1935
10. P.P. Sendi, H.C. Bucher, T. Harr, B.A. Craig, M. Schwietert, and D. Pfluger Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study AIDS 13 1999 1115 1122 (Pubitemid 29361403)
11. Y. Yazdanpanah Costs associated with combination antirretroviral therapy in HIV-infected patients J Antimicrob Chemother 53 2004 558 561 (Pubitemid 38499767)
12. Panel de expertos de GESIDA y Plan Nacional sobre el Sida Documento de consenso de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana Enferm Infecc Microbiol Clin 29 2011 209.e1 209.e103 [Actualizació n Ene 2011]
13. Consejo General de Colegios Oficiales de Farmacéuticos. Portalfarma [Consultado 2 Feb 2011]. Disponible en: https://botplusweb. portalfarma.com/.
14. J.L. Lennox, E. De Jesus, A. Lazzarin, R.B. Pollard, J.V. Ramalho, and D.S. Berger Safety and effi cacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial Lancet 374 2009 796 806
15. P.E. Sax, C. Tierney, A.C. Collier, M.A. Fischl, K. Mollan, and L. Peeples Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy N Engl J Med 361 2009 2230 2240
16. J.E. Gallant, E. De Jesus, J.R. Arribas, A.L. Pozniak, B. Gazzard, and R.E. Campo Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV N Engl J Med 354 2006 251 260 (Pubitemid 43113030)
17. R. Ortiz, E. De Jesus, H. Khanlou, E. Voronin, J. van Lunzen, and J. Andrade-Villanueva Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48 AIDS 22 2008 1389 1397
18. J.M. Molina, J. Andrade-Villanueva, J. Echevarria, P. Chetchotisakd, J. Corral, and N. David Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study Lancet 372 2008 646 655
19. V. Soriano, K. Arasteh, H. Migrone, T. Lutz, M. Opravil, and J. Andrade-Villanueva Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial Antivir Ther 16 2011 339 348
20. J. Gathe, B.A. da Silva, D.E. Cohen, M.R. Loutfy, D. Podzamczer, and R. Rubio A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks J Acquir Immune Defic Syndr 50 2009 474 481
21. S. Walmsley, A. Avihingsanon, J. Slim, D.J. Ward, K. Ruxrungtham, and J. Brunetta Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults J Acquir Immune Defic Syndr 50 2009 367 374
22. K.Y. Smith, P. Patel, D. Fine, N. Bellos, L. Sloan, and P. Lackey Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment AIDS 23 2009 1547 1556
23. J. Eron Jr., P. Yeni, J. Gathe Jr., V. Estrada, E. DeJesus, and S. Staszewski The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial Lancet 368 2006 476 482 (Pubitemid 44160731)
24. E. DeJesus, G. Herrera, E. Teofilo, J. Gerstoft, C.B. Buendia, and J.D. Brand Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults Clin Infect Dis 39 2004 1038 1046 (Pubitemid 39313463)
25. K.Y. Smith, P. Patel, D. Fine, N.C. Bellos, L. Sloan, and P. Lackey Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment AIDS 23 2009 1547 1556